Literature DB >> 17918259

Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data.

Lisa Hazard1, Jonathan D Tward, Aniko Szabo, Dennis C Shrieve.   

Abstract

BACKGROUND: The role of adjuvant radiation therapy in pancreatic cancer is controversial. For the current study, the authors evaluated the effect of preoperative and postoperative radiation therapy on survival in patients with pancreatic adenocarcinoma.
METHODS: The analysis included 3008 patients who were reported to the Surveillance, Epidemiology, and End Results registry of the National Cancer Institute from 1988 to 2002 who had adenocarcinoma of the pancreas and who underwent cancer-directed surgery. A retrospective analysis of overall survival and cancer-specific survival for these patients was performed using the Kaplan-Meier method. Comparative risks of mortality were evaluated by using multivariate-adjusted Cox regression models.
RESULTS: Of 3008 patients, 1267 (42%) received radiation therapy. Overall survival improved significantly in patients who received radiation therapy, with a median survival of 17 months and a 5-year overall survival rate of 13% in patients who received radiation compared with 12 months and 9.7%, respectively, for patients who did not receive radiation therapy (P < .0001). On multivariate analysis, radiation therapy was associated with improvement in overall survival in patients who had direct extension beyond the pancreas and/or regional lymph node involvement (P < .01) but not in patients with T1-T2N0M0 disease (P > .05). Radiation therapy was associated with improvement in cause-specific survival in patients who had regional lymph node involvement (P < .02) but not in patients who had T1-2N0M0 disease or direct extension beyond the pancreas without lymph node involvement (P > .05). Differences in overall and cause-specific survival among patients who received preoperative versus postoperative radiation therapy did not reach statistical significance.
CONCLUSIONS: Radiation therapy was associated with improved survival compared with cancer-directed surgery without radiation in patients with adenocarcinoma of the pancreas. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Year:  2007        PMID: 17918259     DOI: 10.1002/cncr.23047

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.

Authors:  Nedim Turan; Mustafa Benekli; Olcun Umit Unal; İlkay Tugba Unek; Didem Tastekin; Faysal Dane; Efnan Algın; Sukran Ulger; Tulay Eren; Turkan Ozturk Topcu; Esma Turkmen; Nalan Akgül Babacan; Gulnihal Tufan; Zuhat Urakci; Basak Oven Ustaalioglu; Ozlem Sonmez Uysal; Ozlem Balvan Ercelep; Burcu Yapar Taskoylu; Asude Aksoy; Mustafa Canhoroz; Umut Demirci; Erkan Dogan; Veli Berk; Ozan Balakan; Ahmet Şiyar Ekinci; Mukremin Uysal; İbrahim Petekkaya; Selçuk Cemil Ozturk; Önder Tonyalı; Bülent Çetin; Mehmet Naci Aldemir; Kaan Helvacı; Nuriye Ozdemir; İlhan Oztop; Ugur Coskun; Aytug Uner; Ahmet Ozet; Suleyman Buyukberber
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

2.  Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.

Authors:  John A Cieslak; Zita A Sibenaller; Susan A Walsh; Laura L Boles Ponto; Juan Du; John J Sunderland; Joseph J Cullen
Journal:  Radiat Res       Date:  2015-12-31       Impact factor: 2.841

3.  Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States.

Authors:  Erin E Burke; Schelomo Marmor; Pamela R Portschy; Beth A Virnig; Lawrence C Cho; Todd M Tuttle; Eric H Jensen
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

Review 4.  Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

5.  Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Davendra P S Sohal; Erin B Kennedy; Alok Khorana; Mehmet S Copur; Christopher H Crane; Ignacio Garrido-Laguna; Smitha Krishnamurthi; Cassadie Moravek; Eileen M O'Reilly; Philip A Philip; Ramesh K Ramanathan; Joseph T Ruggiero; Manish A Shah; Susan Urba; Hope E Uronis; Michelle W Lau; Daniel Laheru
Journal:  J Clin Oncol       Date:  2018-05-23       Impact factor: 44.544

6.  A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators.

Authors:  Richard Kim; Raymond Tsao; Ann Tan; Mike Byrne; Khaldoun Almhanna; Aleksander Lazaryan; Paul Elson; Robert J Pelley
Journal:  J Gastrointest Surg       Date:  2010-05-06       Impact factor: 3.452

7.  The role of radiotherapy in management of pancreatic cancer.

Authors:  Fen Wang; Parvesh Kumar
Journal:  J Gastrointest Oncol       Date:  2011-09

8.  Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.

Authors:  Andrew M McDonald; Caleb R Dulaney; Javier López-Araujo; James A Posey; Kimberly S Keene; John D Christein; Martin J Heslin; Tina E Wood; Rojymon Jacob
Journal:  J Gastrointest Cancer       Date:  2015-06

9.  Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.

Authors:  John S Moody; Stephen M Sawrie; Kevin R Kozak; John P Plastaras; George Howard; James A Bonner
Journal:  J Gastrointest Cancer       Date:  2009-03-18

10.  A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

Authors:  H Ueno; T Kosuge; Y Matsuyama; J Yamamoto; A Nakao; S Egawa; R Doi; M Monden; T Hatori; M Tanaka; M Shimada; K Kanemitsu
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.